<DOC>
	<DOCNO>NCT00915668</DOCNO>
	<brief_summary>The main purpose research study evaluate effect multiple dose investigational drug know JNJ-31001074 single dose combination oral contraceptive Ovral-L containing ethinyl estradiol levonorgestrel healthy woman bear child . This study look safety , tolerability ( drug make feel ) pharmacokinetics ( body drug ) either drug alone combination healthy woman .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetic Drug Interaction Between Multiple Doses JNJ-31001074 Single Dose Oral Contraceptive Containing Ethinyl Estradiol Levonorgestrel Women</brief_title>
	<detailed_description>This open-label ( physician patient know treatment administer ) , single center randomize , drug-drug interaction study healthy female volunteer non-child bearing potential . A total 32 volunteer enrol . The study consist screen phase , open label treatment period , end study/early withdrawal assessment . Volunteers randomly assign 1 2 treatment sequence . The open-label treatment phase consist two period . In period , volunteer receive either following treatment ( ) : Treatment A : single dose oral contraceptive contain 0.03 mg ethinyl estradiol 0.15 mg levonorgestrel ( Ovral-L ) Day 1 Treatment B : multiple daily dose 10 mg JNJ-31001074 Days 1 8 single dose oral contraceptive contain 0.03 mg ethinyl estradiol 0.15 mg levonorgestrel ( Ovral-L ) Day 7 . A washout ( treatment break drug holiday ) period 28 day separate two occasion single dose administration oral contraceptive Periods 1 2 . Safety tolerability assess time informed consent end-of-study evaluation early withdrawal . Volunteers instruct report serious adverse event occur 30 day follow last dose study drug . For Treatment A , volunteer receive single dose oral contraceptive . For Treatment B , volunteer receive 10 mg tablet JNJ-31001074 daily orally eight day ( Days 1 8 ) single dose oral contraceptive Day 7 .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Women nonchild bear potential ( i.e. , postmenopausal [ spontaneous menses least 2 year ] surgically sterile ) 18 65 year age , inclusive negative pregnancy test body mass index 18 30 body weight great equal 50 kilogram History current clinically significant medical illness abnormal lab value physical exam pregnant lactate use hormonal product 3 month study drug alcohol abuse history smoking nicotine use , 2 week start study clinically significant allergy use prescription nonprescription medication within 2 week start study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Healthy woman</keyword>
	<keyword>Non-childbearing potential</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Oral contraceptive</keyword>
	<keyword>OC</keyword>
	<keyword>Ovral-L</keyword>
	<keyword>ethinyl estradiol</keyword>
	<keyword>EE</keyword>
	<keyword>levonorgestrel</keyword>
	<keyword>JNJ-31001074</keyword>
</DOC>